Virax Biolabs Group Ltd (VRAX) stock
VRAXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends March 31
$0.43−0.02 (-3.39%)
Close on Nov 18, 2026Market cap $249.06KP/E –Yield –
Virax Biolabs revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
For fiscal 2026 it was $12.42K, up 96.2% from the year before. The highest annual figure on record is $156.42K in fiscal 2024.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | $12.42K | +96.2% |
| FY2025 | Mar 31, 2025 | $6.33K | -96.0% |
| FY2024 | Mar 31, 2024 | $156.42K | +1727.1% |
| FY2023 | Mar 31, 2023 | $8.56K | – |
| FY2022 | Mar 31, 2022 | $0 | -100.0% |
| FY2021 | Mar 31, 2021 | $123.82K | – |
See a number that looks wrong?